Genetic Signatures is pleased to share our 2025 Annual Report. The report details the Company’s full financial year results and provides an overview of performance from the Company’s Chair and CEO. Discover our new partnerships and explore the value of syndromic testing for gastrointestinal diseases, highlighted in a compelling case study from a leading UK…

Genetic Signatures is thrilled to welcome our new Chief Technology Officer, Susanne Pedersen, Ph.D. Susanne Pedersen holds a Ph.D. in Molecular Biology and brings over 25 years of experience in oncology and molecular diagnostics. With 13 years leading clinical trial studies from concept to completion, she has a proven track record in building and managing…

Genetic Signatures 2024 AGM, held on 20th of November, warmly farewelled our highly respected and long serving Chair, Dr Nick Samaras, and welcomed Caroline Waldron as Chair. “Caroline Waldron, our incoming Chair, has worked closely with me to facilitate a smooth transition, and on behalf of the Board, I welcome her to the next chapter…

Genetic Signatures’ CEO, Allison Rossiter, brings a distinguished career in healthcare. With a proven track record at Roche Diagnostics, she navigated complex strategic challenges to achieve notable success. Ms Rossiter’s vision and leadership will be invaluable to Genetic Signatures as we enter our next phase of growth. She is warmly welcomed by the team! Allison…

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia. Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior…

A comprehensive and uniquely differentiated multiplex PCR test for gastrointestinal parasites Newtown, New South Wales, Australia, 4th Jun 2024 – Genetic Signatures Limited (ASX: GSS), a leader in molecular diagnostic solutions for infectious disease, announces United States (US) Food and Drug Administration (FDA) 510(k) clearance for its EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated…

Genetic Signatures shares a bittersweet moment as we bid farewell to Dr. John Melki, who has announced his decision to step down as CEO and Director after an illustrious 21 years of leadership. John possesses an extraordinary blend of qualities and skills that have not only inspired, but also motivated and guided our team through a…

A recent article published via Sharecafe discusses Genetic Signatures’ new syndromic EasyScreen™ targets for use in EU and US Markets. To read more Click link

Genetic Signatures Annual Report 2020 released. Click link for more information.